GlassScriptPhysician profile
James W Middleton
NPI 1659337269
$939.28
in general payments reported to CMS, 2019-2025
22 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $170 · 2021: $84.34 · 2022: $35.97 · 2023: $93.98 · 2024: $211 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $288.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $109.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.36 | 2019-2020 | |
| Novo Nordisk INC | $74.70 | 2020-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $39.47 | 2019 | |
| Abbvie INC. | $35.85 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $26.46 | 2023-2024 | Jornay Pm |
| Corium, LLC | $25.92 | 2023-2024 | Azstarys |
| Abiomed | $25.26 | 2024 | Impella |
| Amarin Pharma, INC. | $25.19 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $22.90 | 2021 | |
| Amgen INC. | $20.72 | 2025 | Repatha, Otezla |
| Kyowa Kirin, INC. | $20.30 | 2023 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $19.39 | 2022 | |
| Lundbeck LLC | $18.61 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $17.75 | 2024 | Palynziq |
| Exact Sciences Corporation | $16.98 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.45 | 2025 | Caplyta |
| Mylan Specialty L.P. | $15.36 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $12.40 | 2020 | |
| Genentech USA, INC. | $11.37 | 2019 | |
| Bardy Diagnostics, INC. | $9.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.